Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Multiple Myeloma 64Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Recurrence 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Lymphoma, B-Cell 4Carcinoma, Non-Small-Cell Lung 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Smoldering Multiple Myeloma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia 2Down Syndrome 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thalassemia 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Plasmacytoma 1

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Dexamethasone × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡